scholarly journals Impact of Lymphovascular Invasion on Survival Outcome in Patients With Gastric Cancer

2020 ◽  
Vol 153 (6) ◽  
pp. 833-841
Author(s):  
Di Mei ◽  
Bochao Zhao ◽  
Jiale Zhang ◽  
Rui Luo ◽  
Huiwen Lu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymphovascular Invasion ◽  
Prognostic Significance ◽  
Tumor Stage ◽  
Survival Outcome ◽  
Prognostic Information ◽  
Clinicopathologic Characteristics ◽  
Curative Gastrectomy ◽  
Node Negative ◽  
Impact On Survival

Abstract Objectives To evaluate the prognostic significance of lymphovascular invasion (LVI) for patients with gastric cancer (GC). Methods A total of 1,720 consecutive patients who underwent curative gastrectomy were retrospectively identified. The association between LVI and clinicopathologic characteristics was determined and its impact on survival outcome was evaluated. Results LVI was detected in 21.3% of GC patients, 5.9% of patients with early GC, 24.0% of patients with advanced GC, and 6.7% of node-negative patients using H&E staining. Tumor size (odds ratio [OR], 1.509; 95% confidence interval [CI], 1.159-1.965; P < .01), differentiated type (OR, 1.817; 95% CI, 1.377-2.398; P < .001), and the depth of tumor invasion (OR, 3.011; 95% CI, 2.174-4.171; P < .001) were independent predictive factors for LVI. LVI-positive patients have a poorer prognosis than LVI-negative patients, irrespective of tumor stage or lymph node metastasis. LVI was an independent prognostic factor for patients with GC (hazard ratio, 1.299; 95% CI, 1.112-1.518; P < .001). Conclusions LVI provided additional prognostic information for GC patients, and LVI-positive patients should be considered candidates for adjuvant chemotherapy.

Prognostic Significance of Lymphovascular Invasion in Node-Negative Gastric Cancer

2014 ◽  
Vol 39 (3) ◽  
pp. 732-739 ◽  
Author(s):  
Ju-Hee Lee ◽  
Min Gyu Kim ◽  
Min-Sung Jung ◽  
Sung Joon Kwon
Keyword(s):  
Gastric Cancer ◽  
Lymphovascular Invasion ◽  
Prognostic Significance ◽  
Node Negative

Prognostic significance of immunohistochemical micrometastases in node negative gastric cancer patients

2000 ◽  
Vol 73 (3) ◽  
pp. 153-157 ◽  
Author(s):  
Lawrence E. Harrison ◽  
Jiw K. Choe ◽  
Marsha Goldstein ◽  
Ara Meridian ◽  
Steve H. Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Node Negative ◽  
Gastric Cancer Patients

Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy

2019 ◽  
Vol 42 (4) ◽  
pp. 209-216 ◽  
Author(s):  
Ahmet Bilici ◽  
Fatih Selcukbiricik ◽  
Mesut Seker ◽  
Basak B. Oven ◽  
Omer Fatih Olmez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Ratio ◽  
Metastatic Lymph Node ◽  
Prognostic Significance ◽  
Curative Gastrectomy ◽  
Metastatic Lymph ◽  
Node Ratio

Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 60-60
Author(s):  
Ahmet Bilici ◽  
Dincer Aydin ◽  
Dilek Yavuzer ◽  
Hatice Odabas ◽  
Ozlem Ercelep ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Multivariate Analysis ◽  
Molecular Marker ◽  
Cancer Progression ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Prognostic Indicator ◽  
Curative Gastrectomy ◽  
Prognostic Importance ◽  
Gastric Cancer Patients

60 Background: Tumor invasion and metastasis are complex processes, involving regulation at the molecular level of adhesive molecules, proteolitic enzymes, and cell growth and angiogenesis factors. A Disintegrin and Metalloproteinase (ADAM)17 has been indicated to be indispensable regulator of celular event from proliferation to migration.Although prognostic importance of ADAM17 expression has been investigated in several tumors, its clinical utility as a useful prognostic molecular marker remains unclearin gastric cancer.In the present study, we evaluated the expression of ADAM17 and its prognostic significance in gastric cancer patients after surgery. Methods: Prognostic significance of ADAM17 expression was analyzed by immunohistochemically in 158 patients with gastric cancer and the relationship between its expression and clinicopathological factors was also evaluated. Results: High expression of ADAM17 was detected in 81 patients(51%),while low expression was found in 77 cases (49%). There was significant correlation between gender, histology, lymph node metastasis, vascular invasion, the presence of recurrence and high ADAM17 expression. Recurrence in patients with high ADAM17 expression was significantly higher than that for patients with low ADAM17 expression(p=0.032). The median disease-free survival (DFS) time for patients with high ADAM17 expressed tumors were worse than those of patients with low ADAM17 expressed tumor (16.6 vs. 44.2 months, p=0.004).In addition, patients with low ADAM17 expression had a higher median overall survival (OS)interval than those of high ADAM17 expressed patients (49.6 vs. 26.9 months, p=0.019). Multivariate analysis indicated that the rate of ADAM17 expression was an independent prognostic factor for DFS, in addition to known important clinicopathological prognostic indicator for DFS. But its' prognostic importance could not be proved by multivariate analysis for OS. Conclusions: The potential value of ADAM17 expression as a useful molecular marker in gastric cancer progression should be evaluated comprehensively,it may predict recurrence and poor prognosis in patients with gastric cancer after curative resection.

scholarly journals Prognostic Significance of Preoperative and Postoperative Complement C3 Depletion in Gastric Cancer: A Three-Year Survival Investigation

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Jinning Ye ◽  
Yufeng Ren ◽  
Jianhui Chen ◽  
Wu Song ◽  
Chuangqi Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Significance ◽  
Hospital Costs ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Complement C3 ◽  
Advanced Tumor Stage ◽  
Advanced Tumor ◽  
Prolonged Hospital

Objectives. The role of complement system in predicting prognosis of gastric cancer (GC) remains obscured. This study aims to explore the incidence of complement C3 depletion and associated outcomes in GC patients. Methods. between August 2013 and December 2013, 106 patients with gastric adenocarcinoma were prospectively analyzed. Plasma levels of complement C3 and C4 were detected at baseline, one day before surgery, and postoperative day 3, respectively. Patients with low C3 levels (<0.75 mg/mL) were considered as having complement depletion (CD), while others with normal C3 levels were included as control. The 3-year overall survival (OS), disease-free survival (DFS), and other outcomes were compared between both groups, with the CD incidence explored meanwhile. Results. The CD incidence was 28.3% before surgery but increased to 37.7% after surgery. Preoperative CD was related to prolonged hospital stay (22.7 versus 19.2 day, P=0.032) and increased postoperative complications (33.3% versus 14.5%, P=0.030) and hospital costs (P=0.013). Besides, postoperative C3 depletion was significantly associated with decreased 3-year OS (P=0.022) and DFS (P=0.003). Moreover, postoperative C3 depletion and advanced tumor stage were independent predictive factors of poor prognosis. Conclusions. Complement C3 depletion occurring in gastric cancer was associated with poor short-term and long-term outcomes.

Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy

2015 ◽  
Vol 17 (8) ◽  
pp. 604-611 ◽  
Author(s):  
D. Aydin ◽  
A. Bilici ◽  
D. Yavuzer ◽  
U. Kefeli ◽  
A. Tan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Significance ◽  
Curative Gastrectomy

scholarly journals Clinical utility of CDH17 biomarker in tumor tissues and liquid biopsies for detection and prognostic staging of colorectal cancer (CRC).

2019 ◽  
Vol 5 (suppl) ◽  
pp. 53-53
Author(s):  
Helen Tsoi ◽  
Kwong-Fai Wong ◽  
John M. Luk ◽  
Don Staunton
Keyword(s):  
Gastric Cancer ◽  
Immunohistochemical Staining ◽  
Clinical Utility ◽  
Sandwich Elisa ◽  
Tumor Stage ◽  
Cancer Surveillance ◽  
Cancer Tissue ◽  
Liquid Biopsies ◽  
Prognostic Information ◽  
Tumor Tissues

53 Background: Cancer surveillance using blood-based biomarker tests allows for early cancer detection and more effective prompt treatment. Immunohistochemical staining of tumor-specific antigens can also provide valuable prognostic information and contribute to the design of treatment strategy. Our early studies and work from other investigators have identified cadherin-17 (CDH17) as a promising biomarker in both tumor tissues and liquid biopsies. CDH17 overexpression in cancer tissue was found predictive of poor prognosis in patients with gastric cancer, hepatocellular carcinoma and ovarian cancer. Plasma CDH17 was elevated in patients with gastric cancer when compared to healthy subjects. However, despite the diagnostic and prognostic value of CDH17, robust and accurate assays for CDH17 detection in liquid and tumor biopsies have yet to be developed. Methods: In order to establish CDH17 immunoassays, we have first generated a proprietary library of more than 300 antibodies against CDH17, and from this library, isolated a panel of monoclonal antibodies (mAbs) exhibiting specific and high-affinity binding to the different extracellular domains of CDH17. Results: The immunohistochemical staining of CRC tissues with one of our mAbs revealed a stepwise increase in CDH17 with the progression of cancer from early to late CRC. A sandwich-ELISA was also developed to show significantly elevated plasma CDH17 in patients with CRC when compared to healthy individuals. Like CDH17 expression in CRC tissues, plasma CDH17 also showed a gradual increase with progression to more advanced stages of CRC. The newly developed ELISA also demonstrated that the number of CDH17-containing exosomes was significantly higher in blood isolated from patients with CRC. Notably, our mAbs could also enumerate CDH17-positive circulating tumor cells (CTCs), of which the level was associated with tumor stage. Conclusions: All these findings clearly indicate the clinical utility of CDH17 in tumor tissues and liquid biopsies for detection and prognostic staging of CRC. Further validation of our proprietary CDH17 immunoassays are being conducted in multiple independent CRC cohorts.

Sign in / Sign up

Export Citation Format

Share Document